, /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi (golimumab). Under the agreement, Bio-Thera Solutions ("Bio-Thera") will maintain responsibility for development, manufacturing, and supply of BAT2506. STADA Arzneimittel AG ("STADA") will have exclusive rights to commercialize the product in the European Union (EU), the UK, and selected other countries.
Bio-Thera will receive an upfront payment of , as well as further development and commercial milestones of up to , subject to the fulfillment of certain conditions. "STADA is one of the premier biosimilar companies in , and we are pleased to establish a partnership with STADA for BAT2506", said Dr. , CEO of Bio-Thera.
"We look forward to working with STADA to bring BAT2506 to immunology patients in ." "With global sales in 2023 of , including more than outside of the US, golimumab represents a compelling opportunity to broaden patient access to biological treatments and build scale in immunology alongside our approved adalimumab and ustekinumab biosimilars. Bio-Thera's broad expertise in biologic medicines, including with two biosimilars already approved by the US Food and Drug Administration, makes it an attractive .
